1. X
  2. OncoAlert
Log inSign up
OncoAlert
123.3K posts
Image
user avatar
OncoAlert
@OncoAlert
🌐 Worldwide oncology professionals network | Run by oncologists, for colleagues | All tumor types | Non-profit 🚨 We are #OncoAlert | Oncology360°
Worldwide
OncoAlert360.com
Joined March 2019
137
Following
42.1K
Followers
RepliesRepliesMediaMedia

New to X?

Sign up now to get your own personalized timeline!

Create account

By signing up, you agree to the Terms of Service and Privacy Policy, including Cookie Use.

Terms·Privacy·Cookies·Accessibility·Ads Info·© 2026 X Corp.
Don't miss what's happening
People on X are the first to know.
Log inSign up
  • Pinned
    user avatar
    OncoAlert
    @OncoAlert
    Jul 17
    Does deeper HIF-2α suppression mean better outcomes in Refractory Clear Cell #KidneyCancer? We are here with another #WeekInOncology and no other than our faculty Natalia Gandur from Argentina🇦🇷 to guide us through this great publication Casdatifan shows durable response
    Image
    00:00
    3.2K03.2K
  • user avatar
    OncoAlert
    @OncoAlert
    1m
    Could a lung transplant become a treatment option for carefully selected patients with stage IV lung cancer? New data are challenging one of oncology’s long-standing assumptions. Lung Transplant for Refractory Lung-Limited Stage IV Non–Small Cell Lung Cancer out on JAMA This
    Image
    46046
    user avatar
    OncoAlert
    @OncoAlert
    22s
    Article:
    Image
    Lung Transplant for Lung Cancer
    From jamanetwork.com
  • OncoAlert reposted
    user avatar
    Yüksel Ürün
    @DrYukselUrun
    22h
    Replying to @VincentRK @NEJM and 2 others
    This study reminded me of the landmark 2010 ECOG trial. It started with a simple patient question: “Do we really need this much dexamethasone?” Today we’re asking another: “Do we really need longer maintenance?” Some of the biggest advances in oncology come from questioning “more
    Image
    1900190
  • OncoAlert reposted
    user avatar
    Erman Akkus
    @Erman_Akkus
    18h
    🔴Cancer-associated thrombosis in GI cancers #cancer #oncology #MedX #GI @OncoAlert
    Image
    Made with AI
    2.1K02.1K
  • OncoAlert reposted
    user avatar
    Marianna Valzano
    @MariValzano
    3h
    📢Registration is open for #FlorenceConsensus26. Join leading experts in Florence, 9–10 Oct 2026, for a Multidisciplinary Consensus on the integration of radiotherapy with new systemic treatments. ⏰Free registration | 100 places available. @OncoAlert
    Image
    2020202
  • OncoAlert reposted
    user avatar
    Uğur Özkerim
    @UOzkerim
    22h
    ⁉️ Can adding ipilimumab overcome resistance after progression on nivolumab in recurrent/metastatic HNSCC? The phase II OPTIM trial addressed this question and found no evidence of benefit with nivolumab–ipilimumab. Docetaxel achieved higher ORR (17.6% vs 0%) and longer PFS
    Image
    Image
    2.2K02.2K
  • OncoAlert reposted
    user avatar
    Emre Yekedüz
    @yekeduz_emre
    23h
    Proud to share our new publication from the @EAUYAU_RenalCa EAU Young Academic Urologists (YAU) Renal Cancer Working Group, a great collaborative effort exploring where evidence ends and expert consensus begins in renal cell carcinoma, with key insights from @AUC3_Official 2025.
    Image
    1.1K01.1K
  • OncoAlert reposted
    user avatar
    Uğur Özkerim
    @UOzkerim
    23h
    Real-world evidence for T-DXd in HER2-mutant NSCLC is encouraging. In the multinational TRACER/HERTras cohort (n=168): 🔹 ORR: 55% 🔹 mPFS: 7.2 months 🔹 Intracranial ORR: 74% Patients with active brain metastases were also included, reinforcing the intracranial activity of
    Image
    1.5K01.5K
  • OncoAlert reposted
    user avatar
    Vincent Rajkumar
    @VincentRK
    Jul 18
    MyelomaRisk.com One-stop free-to-use website to risk stratify myeloma, MGUS, smoldering myeloma, Waldenstroms Macroglobulinemia, Amyloidosis. Also links to iStopMM calculator to determine when a bone marrow is needed in MGUS. Will be regularly updated. More
    MyelomaRisk risk calculator preview
    MyelomaRisk - Myeloma Risk Calculator
    From myelomarisk.com
    4.9K04.9K
  • OncoAlert reposted
    user avatar
    Daisuke Kotani, MD, Ph.D 小谷 大輔
    @DaisukeKotani
    Jul 19
    Thrilled to share that our TRIDENTE trial has been accepted for a Rapid Oral Abstract session at #ESMO26 ! Ph2 encorafenib + cetuximab + binimetinib rechallenge in BRAF V600E-mutant mCRC @myESMO @OncoAlert
    Image
    1.8K01.8K
  • OncoAlert reposted
    user avatar
    Daisuke Kotani, MD, Ph.D 小谷 大輔
    @DaisukeKotani
    Jul 19
    Position statement on ADCs in solid tumors The recent pivotal studies & key ongoing studies on ADCs are summarized in Table 1 & 2. 🔗doi.org/10.1016/j.esmo… @ESMO_Open @OncoAlert
    Image
    4.9K04.9K
  • OncoAlert reposted
    user avatar
    Daisuke Kotani, MD, Ph.D 小谷 大輔
    @DaisukeKotani
    Jul 19
    An excellent review article that summarizes therapeutic developments for MSS CRC💊 🔗doi.org/10.1016/j.esmo… @ESMO_Open @OncoAlert
    Image
    4.9K04.9K
  • OncoAlert reposted
    user avatar
    Daisuke Kotani, MD, Ph.D 小谷 大輔
    @DaisukeKotani
    Jul 19
    OPTIM trial: rPh2 of Nivo + Ipi vs DTX after progression on Nivo for HNSCC ◾️ORR: 0% vs 17.6% ◾️PFS: 1.97 vs 3.66 mo (p=0.036) ◾️OS: 3.97 vs 11.9 mo (p=0.356) 👉Nivo + Ipi after progression on Nivo is not recommended for HNSCC. 🔗doi.org/10.1038/s41416… @BrJCancer @OncoAlert
    Image
    Image
    Image
    3.2K03.2K
  • OncoAlert reposted
    user avatar
    Tyler Seibert MD PhD
    @TylerSbrt
    Jul 18
    ✅ MRI 🧲 is best for visualizing prostate, urethra, and #ProstateCancer ❌ But we (usually) need CT/CAT 🐈 for #radonc ☢️⚡️dose calcs 🧵 on MR-CT fusion 🧲🐈 1️⃣
    3.7K03.7K
Advertisement
Advertisement